SEC Form 4 · accession 0001415889-18-000699
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Other
Period of report
May 4, 2018
Accepted (ET)
May 8, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2018 | M | 2,500 | $0.00 | A | 7,507 | D | |
| Common Stock | May 4, 2018 | F | 856 | $86.89 | D | 6,651 | D | |
| Common Stock | holding | — | — | — | 731 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F1,F2 | — | May 4, 2018 | M | 2,500 | D | — | — | Common Stock | 2,500 | 0 | D |
Explanation of responses
- F1The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock.
- F2Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F3The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
Remarks
President, Inflammation and Immunology